Results 11 to 20 of about 1,331,435 (262)

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. [PDF]

PLoS ONE, 2017
Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of
Akiho Fukuda, Kohei Tahara, Yuuki Hane, Toshinobu Matsui, Sayaka Sasaoka, Haruna Hatahira, Yumi Motooka, Shiori Hasegawa, Misa Naganuma, Junko Abe, Satoshi Nakao, Hirofumi Takeuchi, Mitsuhiro Nakamura   +12 more
doaj   +3 more sources

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
BackgroundTeriparatide is approved for osteoporosis. Post-marketing surveillance is critical given its widespread use.ObjectiveTo investigate adverse events (AEs) associated with teriparatide using the FAERS database, compare association strengths for ...
Ming-Tao Wen, Jia-Cheng Li, Jia-Cheng Li, Bo-Wen Lu, Hua-Rong Shao, Pei-Xue Ling, Fei Liu, Fei Liu, Gang Li, Gang Li, Di Luo, Di Luo   +11 more
doaj   +3 more sources

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis [PDF]

, 2020
Background: Adverse drug reactions (ADRs) can occur any time someone uses a medication. ADRs are systematically tracked and cataloged, with varying degrees of success, in order to better understand their etiology and develop methods of prevention.
Zeyun Zhou, Kyle E. Hultgren
openalex   +4 more sources

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system [PDF]

BMC Pharmacology and Toxicology, 2020
Background To describe and analyze the patterns of adverse events associated with dipeptidyl peptidase-4 inhibitors (DPP-4is) (sitagliptin, saxagliptin, linagliptin, vildagliptin, and alogliptin) from the FDA Adverse Event Reporting System (FAERS) and to
Jing Huang, Yuntao Jia, Shusen Sun, Long Meng   +3 more
doaj   +2 more sources

Oseltamivir-induced hepatotoxicity: A retrospective analysis of the FDA adverse event reporting system. [PDF]

PLoS ONE
Assessing the potential for oseltamivir-induced liver damage is essential to ensure its safe administration. The aim of this study was to examine the association between hepatotoxicity and oseltamivir use and to describe the features of oseltamivir ...
Lurong Yu, Qiumeng Xiang, Limei Liu
doaj   +2 more sources

Evaluation of atypical antipsychotics associated rhabdomyolysis using the FDA adverse event reporting system database [PDF]

Scientific Reports
Rhabdomyolysis is a potentially fatal adverse reaction mainly caused by certain medications. Few real-world studies have shown a clear association between atypical antipsychotics and rhabdomyolysis.
Yi Yin, Jie Jiang, Youpeng Jin
doaj   +2 more sources

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) [PDF]

Pharmaceuticals
Background: Canakinumab, a humanized anti-IL-1β monoclonal antibody, is known for its ability to suppress IL-1β-mediated inflammation. However, continuous monitoring of its safety remains essential.
Weidong Zhang, Yunzhou Chen, Zeyu Yao, Mengling Ouyang, Minghui Sun, Shupeng Zou   +5 more
doaj   +2 more sources

Analysis of post-market adverse events of tafamidis base on the FDA adverse event reporting system

Scientific Reports
Tafamidis is the world's first and only oral drug approved to treat the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM). Medicines are known to have different adverse reactions during the course of treatment.
Fan Wu, He Zhu, Yue Zhang
doaj   +3 more sources

A Standardized Dataset of a Spontaneous Adverse Event Reporting System [PDF]

Healthcare, 2022
One of the largest spontaneous adverse events reporting databases in the world is the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). Unfortunately, researchers face many obstacles in analyzing data from the FAERS database. One of the major obstacles is the unstructured entry of drug names into the FAERS, as reporters might ...
Mohammad Ali Khaleel, Amer Hayat Khan, Siti Maisharah Sheikh Ghadzi, Azreen Syazril Adnan, Qasem M. Abdallah   +4 more
openaire   +2 more sources

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]

, 2015
This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Abagyan, Ruben, Ali, Thibault B, Chen, Winston Yuchen, Reilly, Brian M, Schleret, Thomas R   +4 more
core   +9 more sources